Identification of seven cuproptosis-related lncRNAs signature and establishment of a prognostic nomogram predicting overall survival in patients with endometrial cancer

Abstract

Abstract Cuproptosis is a new modality of cell death regulation that is currently considered as a new cancer treatment strategy. However, cuproptosis-related lncRNAs (CRLs) have an unclear relationship with endometrial cancer (EC). In this study, a total of 906 CRLs were identified, and 7 specific cuproptosis-related lncRNAs (AL807761.3, AF131215.7, AC008073.2, AC009229.1, CDKN2A.DT, LINC01615, LINC01166) were selected to conduct a risk model. Patients were divided into high- and low-risk groups according to the median of risk score. The prognosis of the high-risk group was worse than that of the low-risk group, and the predictive accuracy was high (AUC = 0.781), indicating the good reliability and specificity of our risk model. According to Gene Set Variation Analysis (GSVA) and GSEA, both metabolism and cytoskeleton have CRL participation. In addition, we found that the CRLs-related scores were associated with the ESTIMATE score. Stratified survival analysis also revealed that the risk signature have has a high prediction accuracy among people with different clinicopathological characteristics. Further in vitro experimental validation indicated that LINC01615 may promote the invasion of EC cells during progression. The efficient risk model based on seven CRLs has a high prognostic accuracy, and LINC01615 may act as a novel biomarker and therapeutic target for EC patients.